The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | A Phase II study investigating the efficacy of epcoritamab in LBCL post-CAR-T
Allison Marie Bock, MD, University of Utah, Salt Lake City, UT, discusses a Phase II study of epcoritamab for patients with large B-cell lymphomas (LBCLs) achieving a partial response after CD19-directed CAR T-cell therapy. The primary objective of the study is the efficacy of epcoritamab based on conversion to complete response (CR). Inclusion criteria include an absolute neutrophil count (ANC) greater than 1000 /μL and hemoglobin greater than 7/8 g/dL. Patients with active CNS involvement or a history of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) are excluded. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Primum; Consulting or Advisory Role: Abbvie/Pharmacyclics; Research Funding: Abbvie/Pharmacyclics (Inst), Genmab (Inst).
